AR051723A1 - Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva - Google Patents

Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva

Info

Publication number
AR051723A1
AR051723A1 ARP050105284A ARP050105284A AR051723A1 AR 051723 A1 AR051723 A1 AR 051723A1 AR P050105284 A ARP050105284 A AR P050105284A AR P050105284 A ARP050105284 A AR P050105284A AR 051723 A1 AR051723 A1 AR 051723A1
Authority
AR
Argentina
Prior art keywords
treatment
ppar agonists
cardiac insufficiency
congestive cardiac
congestive
Prior art date
Application number
ARP050105284A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR051723A1 publication Critical patent/AR051723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente describe la utilizacion de agonistas del PPAR de las formulas (1) o (2), para el tratamiento de la insuficiencia cardíaca congestiva (CHF).
ARP050105284A 2004-12-17 2005-12-15 Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva AR051723A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04029946A EP1671633A1 (en) 2004-12-17 2004-12-17 Use of PPAR agonists for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
AR051723A1 true AR051723A1 (es) 2007-01-31

Family

ID=34927823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105284A AR051723A1 (es) 2004-12-17 2005-12-15 Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva

Country Status (16)

Country Link
US (1) US7601863B2 (es)
EP (2) EP1671633A1 (es)
JP (1) JP2008524129A (es)
KR (1) KR20070086332A (es)
CN (1) CN101072557A (es)
AR (1) AR051723A1 (es)
AT (1) ATE498400T1 (es)
AU (1) AU2005315920A1 (es)
BR (1) BRPI0519661A2 (es)
CA (1) CA2590391A1 (es)
DE (1) DE602005026443D1 (es)
IL (1) IL183810A0 (es)
MX (1) MX2007006678A (es)
MY (1) MY141010A (es)
TW (1) TW200635584A (es)
WO (1) WO2006063715A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
RS62245B1 (sr) * 2016-10-05 2021-09-30 Mitobridge Inc Oblici kristala i soli jedinjenja ppar agonista

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598278B2 (ja) * 1999-04-28 2010-12-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体
ATE347890T1 (de) * 2001-08-31 2007-01-15 Sanofi Aventis Deutschland Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren
US20050020654A1 (en) * 2003-03-15 2005-01-27 Pershadsingh Harrihar A. Novel PPAR agonists, pharmaceutical compositions and uses thereof
US6989462B2 (en) * 2003-03-25 2006-01-24 Sanofi-Aventis Deutschland Gmbh Synthesis of 2-chloromethyl-6-methylbenzoic ester
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators

Also Published As

Publication number Publication date
TW200635584A (en) 2006-10-16
EP1827425B1 (en) 2011-02-16
BRPI0519661A2 (pt) 2009-03-03
MX2007006678A (es) 2007-08-14
CN101072557A (zh) 2007-11-14
AU2005315920A1 (en) 2006-06-22
ATE498400T1 (de) 2011-03-15
US7601863B2 (en) 2009-10-13
US20080039512A1 (en) 2008-02-14
KR20070086332A (ko) 2007-08-27
IL183810A0 (en) 2007-10-31
WO2006063715A1 (en) 2006-06-22
JP2008524129A (ja) 2008-07-10
EP1827425A1 (en) 2007-09-05
DE602005026443D1 (de) 2011-03-31
MY141010A (en) 2010-02-25
CA2590391A1 (en) 2006-06-22
EP1671633A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
CY1122964T1 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
EA200701918A1 (ru) Белок липокалин
RS52784B (en) They're TANATE RAZAGILINA
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CL2009001044A1 (es) Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades.
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
EA200701592A1 (ru) Композиты и способы их получения и использования
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
MD3615544T2 (ro) Compuși antitumorali
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
CL2007001747A1 (es) Compuestos derivados de aril y heteroaril-etil-acilguanidina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y prevencion de la hipertension, insuficiencia cardiaca y afecciones renales entre otras.
AR051723A1 (es) Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
GT200800296A (es) Derivados de ácido fenilacético
UY29259A1 (es) Utilización de agonistas del ppar para el tratamiento de la insuficiencia cardíaca congestiva
NO20062384L (no) Anvendelse av BH4 for bahandling av respiratoriske sykdommer
UA126152U (uk) Цис-2-(трифлуорометил)циклогексилметиламін

Legal Events

Date Code Title Description
FA Abandonment or withdrawal